Join
Live feed
·
PRReleasevia Quantisnow
Allogene Therapeutics Inc. logo

Allogene Therapeutics Announces Nature Communications Publication Highlighting Pre-Clinical Data for ALLO-329, a Next Generation Dual-Targeted CD19/CD70 Allogeneic CAR T for Autoimmune Diseases

ByQuantisnow·Wall Street's wire, on your screen.
ALLO· Allogene Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ALLO (Allogene Therapeutics Inc.) and more on Quantisnow.